Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The CAMS Oxford Institute has prioritised funding support in response to the current crisis caused by nCoV 2019, supporting positive actions taken by the Medical Sciences Divisions and University of Oxford.

image of a virus

Projects include:

  • Studies on the structural biology of the new virus led by David Stuart and Yvonne Jones, which will be important to evaluate the Vaccine and drug efficacy
  • Studies on the protective immune responses in patients led by Tao Dong; Production of humanised monoclonal antibodies led by Gavin Screaton, Juthathip Mongkolsapaya, Alain Townsend and Pramila Rijal which we hope will be therapeutic and also inform vaccine design
  • Vaccine design with novel reagents developed in Oxford led by Alain Townsend and Pramila Rijal
  • Understand the nature and drives of disease severity in Novel Coronavirus led by Julian Knight and Jianwei Wang
  • Identification of correlates of protection of ChAdOx1 nCoV-19 against COVID -19 led by Teresa Lambe and Sarah Gilbert in collaboration with Tao Dong and Yonghong Zhang to mapping the human immune responses post-vaccination with ChAdOx1 nCoV-19, in comparison with naturally infected individuals.

The COI will also act as a central hub to facilitate collaborations between Oxford and China supported by Oxford Medical Science Division and to provide help and support in the area of epidemiology, designing clinical trials, working on the structural biology of the new virus in addition to above mentioned project.

Further details are available here.


Similar stories

COVID-19 Impact Report

To date, the CAMS-Oxford Institute (COI) has funded 11 COVID-19 projects aiming to understand immune responses to COVID-19, contributing 18 published research articles to the field. Read about the impact the COI has had on our understanding of COVID-19 pathology and immunology.

Strong cytotoxic T cell responses to an internal viral component are associated with mild COVID-19 disease

Study from the Dong Group reveals key differences in the adaptive immune responses of patients with mild vs. severe COVID-19, highlighting a potential new vaccine target.

COVID Without Borders: Diagnostics and Treatment for COVID-19

The CAMS-COI Joint webinar entitled “COVID Without Borders-A collaboration to Investigate A New Disease III – Diagnostic and Treatment for COVID-19” was held online on the morning of November 17th 2020.

Oxford University breakthrough on global COVID-19 vaccine

The University of Oxford, in collaboration with AstraZeneca plc, today announces interim trial data from its Phase III trials that show its candidate vaccine, ChAdOx1 nCoV-2019, is effective at preventing COVID-19 (SARS-CoV-2) and offers a high level of protection.

COVID Without Borders: Vaccine Research and Development

The webinar entitled “COVID Without Borders: A collaboration to Investigate a New Disease II - Vaccine Research and Development” was held online on 22nd September 2020.

COVID Without Borders: A collaboration to Investigate A New Disease

On the morning of 1st July 2020, the webinar “COVID Without Borders: A collaboration to Investigate A New Disease” was held online.